Phase 4 N=90 Physiologic Approach to Sodium Supplementation in Premature Infants
Postnatal Growth Disorder
Primary: Change in Somatic Growth (Weight) — 0.04; 0.16 score on a scale — p=0.162
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - Part I
Uveomeningoencephalitic Syndrome · Inflammation · Choroid Disease
Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001
Phase 1 N=251 A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults
Healthy
Primary: SSA: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 49.6; 52.0; 20.8; 28.0 Percentage of participants
N/A N=50 Validation and Cross-cultural Adaptation of Croatian SECEL Questionnaire
Larynx Neoplasm · Laryngectomy; Status · Communication
Primary: Means, Standard Deviations (Ranges), Test-retest Reliability of the Self- Evaluation of Communication Experiences After Laryngectomy (SECEL:HR) Questionnaire — 4.69…
Phase 1 N=184 Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
Advanced Malignancies
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 2; 5; 5; 33 Participants
N/A N=6,718 Transthyretin Amyloidosis Outcome Survey (THAOS)
Transthyretin Gene Mutations · Transthyretin Amyloidosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 621; 175; 66; 4 Participants
Phase 3 N=71 A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
Chronic Spontaneous Urticaria
Primary: Number of Participants With Treatment Emergent Adverse Events — 62; 0; 3; 1 Participants
Phase 4 N=103 Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Primary: Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections — 0; 0 Events
Phase 3 N=10 The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Change in Absorption of Wet Weight/Fluids — 841.6; 1240.0 g/day — p== 0.0585
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
N/A N=451 Leveraging mHealth and Peers to Engage African- Americans and Latinxs in HIV Care (LEAN)
HIV/AIDS
Primary: Participants With HIV Viral Load Suppression (Copies/cc) — 114; 128; 38; 32 Participants
Phase 2 N=155 Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
Psoriasis
Primary: PASI 75 - Week 12 (EoT) — 4; 4; 1; 46 Participants — p=0.161
Phase 1 N=44 Voxelotor CYP and Transporter Cocktail Interaction Study
Sickle Cell Disease
Primary: Part A: Maximum Observed Plasma Concentration (Cmax) for Bupropion — 160.5; 201.3; 191.1 Nanogram per milliliter (ng/mL)
N/A N=700 Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
Cervical Cancer
Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants
N/A N=32 Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
Smoking, Tobacco
Primary: Maximum Plasma Concentration [Cmax] — 8.425; 7.475; 13.43 ng/mL